RBC Affirms PTC Therapeutics (PTCT) at 'Sector Perform'; Doesn't See Translarna Appeal with Solid Chance
- Health, tech stocks extend Wall Street record-setting rally
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
- Exclusive: Japan's TDK in talks to buy iPhone supplier InvenSense - sources
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
RBC Capital affirms PTC Therapeutics, Inc. (Nadaq: PTCT) at Sector Perform with a price target of $5 after the company announced that at the end of last week, the Office of Drug Evaluation I (ODE-I) of the U.S. Food and Drug Administration (FDA) denied the company's first appeal of the refuse to file letter issued by the FDA's Division of Neurological Products (DNP) on February 22, 2016 regarding PTC's New Drug Application (NDA) for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
RBC noted that PTC will escalate the effort. The firm commented,
we think that PTCT does not have much of a leg to stand on on this effort. The simple reason is that while eteplirsen's dataset may indeed be weak and incomplete (again, we agree 100% with this view), and thus we may truly not know right now whether eteplirsen works, this also means that there is a real possibility that eteplirsen could actually work and indeed provide a real benefit to DMD patients. We just don't know this from the existing eteplirsen dataset, and thus one could buy FDA's argument that it had to make eteplirsen available to patients (NOTE: again, we don't personally agree with this argument; we're stating what the argument for eteplirsen's approval was).
This, however, is NOT the case with ataluren. The reason is that ataluren has failed to show a benefit to patients in two large, randomized, placebo-controlled trials, the second one of which was designed based on the subset of patients that did show a benefit on a post-hoc analysis of the first failed trial. In addition to the two failed trials in DMD, this compound failed to show a benefit in a third, large, randomized, placebo-controlled trial in an additional indication (CF). Therefore, while we still disagree with FDA's decision to approve eteplirsen, given the weak/incomplete dataset, we can at least agree with FDA that we don't know with certainty that it does not help patients.
Shares of PTC Therapeutics closed at $13.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Discusses Biogen (BIIB) Seizure Patient
- BMO Capital Raises Price Target on Dollar Tree (DLTR) to $96; Reiterates Market Perform
- BMO Capital Cuts Price Target on Cooper Cos. (COO) Following 4Q Results
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!